Moderna Sees 41 Percent Q2 Revenue Drop as COVID Vaccine Sales Decline
Moderna posted USD 142 million in revenue for the second quarter 2025, down 41 percent from USD 241 million in the same period last year.
Moderna | 04/08/2025 | By Dineshwori
Moderna reports positive results from phase 3 efficacy study of P304 for seasonal influenza vaccine
In a previous phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine.
Moderna | 02/07/2025 | By Darshana | 121
Moderna Gets MHRA Authorization for Updated COVID-19 Vaccine
For the first time in the UK, the updated vaccine, Spikevax JN.1, will also be available to purchase privately for those who are not eligible for the NHS Autumn vaccination program.
Moderna | 05/09/2024 | By Aishwarya | 212
Moderna and Mitsubishi Tanabe Pharma to Promote mRNA Respiratory Vaccine in Japan
Moderna, Inc. has signed a joint agreement with Mitsubishi Tanabe Pharma regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
Moderna | 15/07/2024 | By Aishwarya | 324
Global diseases treatment with mRNA to be researched by Moderna and IAVI together
Moderna and IAVI, a nonprofit scientific research organization, are teaming up to use mRNA to develop new therapies for a range of diseases like HIV / AIDS, Tuberculosis, anti-microbial-resistant enteric infection and COVID-19.
Moderna | 12/04/2022 | By Sudeep Soparkar | 558
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy